Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03786081 |
Recruitment Status :
Active, not recruiting
First Posted : December 24, 2018
Last Update Posted : February 12, 2024
|
Sponsor:
Seagen Inc.
Collaborators:
Genmab
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Belgian Gynaecological Oncology Group
GOG Foundation
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Seagen Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | December 31, 2024 |
Estimated Study Completion Date : | December 31, 2024 |